ReviR Therapeutics received an undisclosed amount of funding to advance its pipeline of disease-modifying RNA-targeting therapies for the treatment of Huntington’s disease and Charcot-Marie-Tooth disease, both rare neurological disorders.
ReviR Therapeutics received an undisclosed amount of funding to advance its pipeline of disease-modifying RNA-targeting therapies for the treatment of Huntington’s disease and Charcot-Marie-Tooth disease, both rare neurological disorders.